Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC

Key Points

• Blue Owl Capital Holdings initiated a 400,000-share position in Oric Pharmaceuticals valued at approximately $4.33 million, representing about 0.39% of ORIC and 0.7% of Blue Owl’s portfolio.
• Institutional ownership remains high at 95.05%, with BlackRock, Vanguard, State Street, Orbimed Advisors, and T. Rowe Price among major investors that recently increased or initiated positions.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and an average price target of $19.45, although ORIC recently fell 5.3% to $13.88 and reported a quarterly EPS loss of $0.38, missing estimates.

Blue Owl Capital Holdings LP bought a new stake in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 400,000 shares of the company's stock, valued at approximately $4,332,000. Oric Pharmaceuticals makes up approximately 0.7% of Blue Owl Capital Holdings LP's portfolio, making the stock its 25th biggest position. Blue Owl Capital Holdings LP owned approximately 0.39% of Oric Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ORIC. BlackRock Inc. purchased a new position in shares of Oric Pharmaceuticals during the second quarter valued at about $73,904,000. Vanguard Group Inc. grew its holdings in shares of Oric Pharmaceuticals by 48.8% during the 3rd quarter. Vanguard Group Inc. now owns 4,650,138 shares of the company's stock worth $55,802,000 after acquiring an additional 1,525,445 shares during the period. State Street Corp grew its holdings in shares of Oric Pharmaceuticals by 77.1% during the 4th quarter. State Street Corp now owns 4,258,397 shares of the company's stock worth $34,834,000 after acquiring an additional 1,854,458 shares during the period. Orbimed Advisors LLC raised its position in shares of Oric Pharmaceuticals by 305.0% in the 3rd quarter. Orbimed Advisors LLC now owns 3,641,756 shares of the company's stock worth $43,701,000 after acquiring an additional 2,742,475 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Oric Pharmaceuticals by 14.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,295,122 shares of the company's stock valued at $26,955,000 after purchasing an additional 423,795 shares during the period. Hedge funds and other institutional investors own 95.05% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ORIC. HC Wainwright increased their price objective on Oric Pharmaceuticals from $25.00 to $27.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Wall Street Zen upgraded shares of Oric Pharmaceuticals from a "strong sell" rating to a "sell" rating in a report on Saturday, July 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Oric Pharmaceuticals in a research note on Friday, July 17th. Cantor Fitzgerald reissued an "overweight" rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. Finally, The Goldman Sachs Group raised shares of Oric Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $15.00 price target for the company in a research report on Friday, May 15th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $19.45.

Oric Pharmaceuticals Trading Down 5.3%

NASDAQ ORIC opened at $13.88 on Friday. Oric Pharmaceuticals, Inc. has a 12 month low of $7.23 and a 12 month high of $14.93. The stock has a market cap of $1.44 billion, a P/E ratio of -10.28 and a beta of 1.02. The stock's fifty day moving average price is $11.22 and its 200-day moving average price is $10.60.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.02). As a group, analysts forecast that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current fiscal year.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.

Want to see what other hedge funds are holding ORIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source